TABLE 1.
Main demographic and disease characteristics of patients at baseline
| Characteristics | n°= 339 |
|---|---|
| Median age, years (IQR) | 67 (59–74) |
| Male, n (%) | 203 (60) |
| Myeloma subtype, n (%) | |
|
•IgG •IgA •IgD •IgM |
253 (75) 81 (24) 4 (1) 1 (<1) |
| Involved sFLC, n (%) | |
|
•kappa •lambda |
228 (67) 111 (33) |
| sFLCR, n (%) | |
|
•abnormal •normal (0.26–1.65) |
311 (92) 28 (8) |
| Involved sFLC >100 mg/L with abnormal sFLCR, n (%) | 231 (68) |
| Serum creatinine ≥1.2 mg/dL, n (%) | 101 (30) |
| ISS stage, n (%) a | |
|
•I •II •III |
92 (33) 99 (35) 91 (32) |
| Centralized FISH analysis for CA, n (%) b | |
|
•del(17p) and/or t(4;14) and/or t(14;16) positivity •del(17p) and t(4;14) and t(14;16) negativity |
70 (32) 152 (69) |
| First‐line treatment, n (%) | |
|
•PIs •IMiDs •PIs + IMiDs •ASCT |
141 (42) 45 (13) 153 (45) 164 (48) |
Abbreviations: ASCT, autologous stem cell transplantation; CA, cytogenetic abnormalities; FISH, fluorescence in situ hybridization; IMiDs, immunomodulatory drugs; ISS, international staging system; PIs, proteasome inhibitors; sFLC, serum‐free light chain; sFLCR, serum‐free light chain ratio.
282 patients were available for assessment.
222 patients were available for assessment.